 |
 |
|
15 November 1997 | Volume 127 Issue 10 | Pages 875-881
Background: Less than 20% of patients with chronic hepatitis C have a sustained response to interferon-
Objective: To determine the long-term biochemical, virologic, and histologic outcomes in patients with chronic hepatitis C who have a sustained response to interferon-
Design: Prospective cohort study.
Setting: University hospital.
Patients: 80 patients who had chronic hepatitis C, had a sustained biochemical and virologic response to interferon-
Measurements: Serum hepatitis C virus (HCV) RNA detected by polymerase chain reaction (PCR); HCV genotyping determined by line probe assay; liver histologic studies; liver HCV RNA detected by PCR on frozen liver tissue samples (in 27 patients); and repeated measurements of serum alanine aminotransferase (ALT) levels. Liver biopsy was done before treatment in all 80 patients, and at least one biopsy was done in 69 patients 1 to 6 years after treatment.
Results: The 80 patients had follow-up 1 to 7.6 years (mean ±SD, 4.0 ± 2.0 years) after interferon-
Conclusions: In patients with chronic hepatitis C who have persistently normal serum ALT levels and no detectable serum HCV RNA 6 months after interferon-
Author and Article Information
From Hopital Beaujon, Clichy, France.
ARTICLE
Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-
Therapy
therapy. The long-term benefit of interferon- with regard to hepatic viral clearance and histologic improvement remains unknown. therapy. therapy, and were followed for at least 12 months. treatment. The follow-up period was 1, 2, 3, 4, 5, 6, and more than 6 years in 11, 13, 14, 18, 10, 12, and 2 patients, respectively, after the end of therapy. During the entire follow-up period, 93% (95% CI, 84% to 97%) of patients had persistently normal serum ALT levels. Serum HCV RNA remained undetectable in 96% (CI, 89% to 99%) of patients. A comparison of liver histologic findings before and 1 to 6.2 years after interferon- treatment showed a clear improvement in 94% (CI, 83% to 99%) of patients. In 62% of patients, the last biopsy done showed normal or nearly normal histologic findings. Liver HCV RNA was detectable before treatment in all 13 patients tested and was undetectable 1 to 5 years after treatment in all 27 patients tested. therapy, a long-term sustained biochemical and virologic response is generally seen. This response is associated with an absence of detectable intrahepatic HCV RNA and marked histologic improvement.
Acknowledgments: The authors thank Drs. C. Lemonnier and C. Langlois (Schering-Plough Corp.) for their support.
Grant Support: In part by a grant from the Association pour la Recherche contre le Cancer.
Requests for Reprints: Patrick Marcellin, MD, Service d'Hepatologie, Hopital Beaujon, 100 Boulevard du General Leclerc, 92118 Clichy, France.
Current Author Addresses: Drs. Marcellin, Boyer, Gervais, Pouteau, Castelnau, Kilani, Areias, Auperin, Benhamou, and Erlinger and Ms. Martinot: Service d'Hepatologie and Unite de Recherches de Physiopathologie Hepatique (INSERM U24), Hopital Beaujon, 100 Boulevard du General Leclerc, 92118 Clichy, France.
Related articles in Annals:
2b in Patients with Histologically Mild Chronic Hepatitis C Therapy for Chronic Hepatitis C for Chronic Hepatitis C: Reducing the UncertaintiesThis article has been cited by other articles:
|
|
 |
|
  A. E. Duggan, J. M. Duggan, N. Assy, O. Embon, A. Evoli, S. Servidei, C. Ben Salem, H. Hmouda, K. Bouraoui, S. Leiner, et al. Peginterferon and Ribavirin for Hepatitis C N. Engl. J. Med., March 22, 2007; 356(12): 1269 - 1271. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Scott and D. R. Gretch Molecular Diagnostics of Hepatitis C Virus Infection: A Systematic Review JAMA, February 21, 2007; 297(7): 724 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. S. Khader, A. Dweek, A. Alkafajei, and A. Z. Rabi' Combination Therapy of Interferon and Ribavirin Versus Interferon Monotherapy in Treatment of Chronic Hepatitis C: A Meta-analysis of Clinical Trials Journal of Pharmacy Practice, October 1, 2006; 19(5): 265 - 274. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Wong and S. S. Lee Hepatitis C: a review for primary care physicians Can. Med. Assoc. J., February 28, 2006; 174(5): 649 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Paris, M. M. Pradhan, S. Allen, and W. M. Cassidy Cost of Hepatitis C Treatment in the Correctional Setting Journal of Correctional Health Care, April 1, 2005; 11(2): 199 - 212. [Abstract] [PDF]
|
|
|
|
 |
|
 B J Veldt, G Saracco, N Boyer, C Camma, A Bellobuono, U Hopf, I Castillo, O Weiland, F Nevens, B E Hansen, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy Gut, October 1, 2004; 53(10): 1504 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Hadziyannis, H. Sette Jr., T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer Jr., D. Bernstein, M. Rizzetto, et al. Peginterferon-{alpha}2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Ann Intern Med, March 2, 2004; 140(5): 346 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zeuzem Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? Ann Intern Med, March 2, 2004; 140(5): 370 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Dhumeaux, P Marcellin, and E Lerebours Treatment of hepatitis C. The 2002 French consensus Gut, December 1, 2003; 52(12): 1784 - 1787. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Salomon, M. C. Weinstein, J. K. Hammitt, and S. J. Goldie Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population JAMA, July 9, 2003; 290(2): 228 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sulkowski and D. L. Thomas Hepatitis C in the HIV-Infected Person Ann Intern Med, February 4, 2003; 138(3): 197 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Bizollon, S N S Ahmed, S Radenne, M Chevallier, P Chevallier, P Parvaz, S Guichard, C Ducerf, J Baulieux, F Zoulim, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence Gut, February 1, 2003; 52(2): 283 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L Kjaergard, K. Krogsgaard, and C. Gluud Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials BMJ, November 17, 2001; 323(7322): 1151 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Jacobson, L. Feinman, L. Liebes, N. Ostrow, V. Koslowski, A. Tobia, B. E. Cabana, D.-H. Lee, J. Spritzler, and A. M. Prince Pharmacokinetics, Safety, and Antiviral Effects of Hypericin, a Derivative of St. John's Wort Plant, in Patients with Chronic Hepatitis C Virus Infection Antimicrob. Agents Chemother., February 1, 2001; 45(2): 517 - 524. [Abstract] [Full Text]
|
|
|
|
|
|
R. S. Koff Nonresponse to Interferon in Chronic Hepatitis C: Re-treatment Redux JAMA, January 10, 2001; 285(2): 212 - 214. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Wong and R. S. Koff Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med, November 7, 2000; 133(9): 665 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Butkiewicz, N. Yao, W. Zhong, J. Wright-Minogue, P. Ingravallo, R. Zhang, J. Durkin, D. N. Standring, B. M. Baroudy, D. V. Sangar, et al. Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3 J. Virol., May 1, 2000; 74(9): 4291 - 4301. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Shiratori, F. Imazeki, M. Moriyama, M. Yano, Y. Arakawa, O. Yokosuka, T. Kuroki, S. Nishiguchi, M. Sata, G. Yamada, et al. Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy Ann Intern Med, April 4, 2000; 132(7): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The National Commission on Correctional Health Care and The Society of Correctional Physicians Joint Position Statement: The Management of Hepatitis C in Correctional Institutions Journal of Correctional Health Care, March 1, 2000; 7(1): 149 - 155. [PDF]
|
|
|
|
|
|
K. S. Gutfreund and V. G. Bain Chronic viral hepatitis C: management update Can. Med. Assoc. J., March 1, 2000; 162(6): 827 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Liang, B. Rehermann, L. B. Seeff, and J. H. Hoofnagle Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med, February 15, 2000; 132(4): 296 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Baffis, I. Shrier, A. H. Sherker, and A. Szilagyi Use of Interferon for Prevention of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis B or Hepatitis C Virus Infection Ann Intern Med, November 2, 1999; 131(9): 696 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M BONACINI, A G REDEKER;, and G H HAYDON Intrahepatic HCV levels in chronic HCV infection • Reply Gut, October 1, 1999; 45(4): 630a - 630. [Full Text]
|
|
|
|
|
|
R. S. Koff Advances in the Treatment of Chronic Viral Hepatitis JAMA, August 11, 1999; 282(6): 511 - 512. [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Pawlotsky, G. Germanidis, P.-O. Frainais, M. Bouvier, A. Soulier, M. Pellerin, and D. Dhumeaux Evolution of the Hepatitis C Virus Second Envelope Protein Hypervariable Region in Chronically Infected Patients Receiving Alpha Interferon Therapy J. Virol., August 1, 1999; 73(8): 6490 - 6499. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ferrari, J. Wright-Minogue, J. W. S. Fang, B. M. Baroudy, J. Y. N. Lau, and Z. Hong Characterization of Soluble Hepatitis C Virus RNA-Dependent RNA Polymerase Expressed in Escherichia coli J. Virol., February 1, 1999; 73(2): 1649 - 1654. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. McHutchison, S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M.-H. Ling, S. Cort, J. K. Albrecht, et al. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C N. Engl. J. Med., November 19, 1998; 339(21): 1485 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M.-H. Ling, et al. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C N. Engl. J. Med., November 19, 1998; 339(21): 1493 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S W SCHALM and S W SCHALM Adding ribavirin to interferon alpha -2b for chronic hepatitis C infection increased virological response and nausea • Commentary Gut, November 1, 1998; 43(5): 602 - 602. [Full Text] [PDF]
|
|
|
|
|
|
M BERENGUER and T L WRIGHT Is the hepatocyte a Trojan horse for hepatitis C virus? Gut, April 1, 1998; 42(4): 456 - 458. [Full Text]
|
|
|
|
 |
|
 INTERFERON-ALPHA FOR HEPATITIS C: IS IT WORTH IT? Journal Watch (General), December 12, 1997; 1997(1212): 1 - 1. [Full Text]
|
|
Article
